Ignite Creation Date:
2024-05-05 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00488683
Status:
COMPLETED
Last Update Posted:
2014-10-01
First Post:
2007-06-19
Brief Title:
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Sponsor:
Novartis Vaccines
Organization:
Novartis
Study Overview
Official Title:
A Phase II Single Center Open-label Randomized Study to Investigate Meningococcal Serogroup A C W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Status:
COMPLETED
Status Verified Date:
2014-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is aimed to assess whether the frequency of meningococcal serogroup A C W-135 and Y specific memory B Cells measured 1 month after a primary vaccination series of Novartis MenACWY vaccine predicts the specific serum bactericidal activity using human complement hSBA of respectively serogroup A C W-135 and Y at 12 months of age
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-003476-35 | None | None | None |